Potential Rescheduling of Marijuana by Trump Administration Leads to Tilray Brands Stock Surge

Summary

Tilray Brands (TLRY) shares surged between 11% and 18% following reports that the Trump administration plans to reclassify marijuana from a Schedule I to a Schedule III drug benzinga_article+ 2. This regulatory shift, expected via executive order, would officially recognize the medical utility of cannabis and significantly lower the tax burden for operators by removing Section 280E restrictions Sina Finance.

Impact Analysis

This isn’t just another ‘pot stock’ rally; it’s a fundamental repricing of survival. The move to Schedule III is really about killing the 280E tax penalty, which has been strangling Tilray’s margins—last reported at 26.58% with a $26.57M net loss . By allowing banking access and medical research, the administration is effectively professionalizing the sector Sina Finance+ 2. The market’s reaction was violent, with TLRY hitting a high of $8.16 , but don’t ignore the technicals: we’re hitting heavy resistance at $8.00 and the stock is hugging its upper Bollinger Band, signaling a potential short-term pullback benzinga_article. While short-term momentum is bullish (MACD golden cross), prediction markets are still skeptical, pricing only a 32% chance of completion by June benzinga_article. I’d read this as a high-conviction trade on tax reform, but with most holders still underwater at an average cost of $11.29, expect heavy selling pressure if the executive order faces any legal delays benzinga_article. Watch the $8.00 level closely.